A comparison of external beam radiation therapy versus radical prostatectomy for patients with low risk prostate carcinoma diagnosed, staged, and treated at a single institution

The authors retrospectively reviewed their institution's long term experience treating a group of comparably staged low risk prostate carcinoma patients with either radical prostatectomy or external beam radiation therapy (RT) to determine whether the method of treatment resulted in significant differences in biochemical control and/or survival.

[1]  C. Ling,et al.  Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. , 1999, International journal of radiation oncology, biology, physics.

[2]  S B Malkowicz,et al.  Biochemical Outcome After Radical Prostatectomy , External Beam Radiation Therapy , or Interstitial Radiation Therapy for Clinically Localized Prostate Cancer , 2000 .

[3]  William R. Fair,et al.  DOSE ESCALATION WITH THREE-DIMENSIONAL CONFORMAL RADIATION THERAPY AFFECTS THE OUTCOME IN PROSTATE CANCER , 1998 .

[4]  T E Schultheiss,et al.  Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. , 1998, International journal of radiation oncology, biology, physics.

[5]  R. Valicenti,et al.  Stage T3 prostate cancer: a nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy. , 1998, Urology.

[6]  F. Vicini,et al.  Radiotherapy options for localized prostate cancer based upon pretreatment serum prostate-specific antigen levels and biochemical control: a comprehensive review of the literature. , 1998, International journal of radiation oncology, biology, physics.

[7]  A. Pollack,et al.  External beam radiotherapy for stage T1/T2 prostate cancer: how does it stack up? , 1998, Urology.

[8]  A. Martinez,et al.  The correlation between the ASTRO Consensus Panel definition of biochemical failure and clinical outcome for patients with prostate cancer treated with external beam irradiation. American Society of Therapeutic Radiology and Oncology. , 1998, International journal of radiation oncology, biology, physics.

[9]  A. D'Amico,et al.  Equivalent 5-year bNED in select prostate cancer patients managed with surgery or radiation therapy despite exclusion of the seminal vesicles from the CTV. , 1997, International journal of radiation oncology, biology, physics.

[10]  F. Vicini,et al.  Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. , 1997, The Journal of urology.

[11]  H. Levin,et al.  Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery? , 1997, International journal of radiation oncology, biology, physics.

[12]  A. D'Amico,et al.  Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of > 4-20 ng/ml. , 1997, International journal of radiation oncology, biology, physics.

[13]  James D. Cox,et al.  Consensus statement: Guidelines for PSA following radiation therapy , 1997 .

[14]  H. Levin,et al.  External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. , 1997, The cancer journal from Scientific American.

[15]  T E Schultheiss,et al.  Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. , 1997, International journal of radiation oncology, biology, physics.

[16]  The management of clinically localized prostate cancer: Guidelines from the American Urological Association , 1996, CA: a cancer journal for clinicians.

[17]  F. Vicini,et al.  Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. , 1996, International journal of radiation oncology, biology, physics.

[18]  J. Oesterling,et al.  Prostate Cancer Clinical Guidelines Panel Summary report on the management of clinically localized prostate cancer. The American Urological Association. , 1995, The Journal of urology.

[19]  M. Kattan,et al.  Prognostic significance of positive surgical margins in radical prostatectomy specimens. , 1995, The Journal of urology.

[20]  D. Wood,et al.  Randomized Prospective Study Comparing Radical Prostatectomy Alone Versus Radical Prostatectomy Preceded by Androgen Blockage in Clinical Stage B2 (T2bNxM0) Prostate Cancer , 1995 .

[21]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[22]  D. Wood,et al.  Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. , 1995, The Journal of urology.

[23]  J. Oesterling,et al.  Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. , 1994, The Journal of urology.

[24]  J E Fowler,et al.  Prostate specific antigen progression rates after radical prostatectomy or radiation therapy for localized prostate cancer. , 1994, Surgery.

[25]  N. Olson,et al.  Analysis of risk factors associated with prostate cancer extension to the surgical margin and pelvic node metastasis at radical prostatectomy. , 1993, The Journal of urology.

[26]  Galina Pizov,et al.  Correlation of pathologic findings with progression after radical retropubic prostatectomy , 1993, Cancer.

[27]  T. Stamey,et al.  Positive surgical margins at radical prostatectomy: importance of the apical dissection. , 1990, The Journal of urology.

[28]  W. Catalona,et al.  Nerve-sparing radical prostatectomy: evaluation of results after 250 patients. , 1990, The Journal of urology.

[29]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[30]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .